A randomized trial of adjunct testosterone for cancer-related muscle loss in men and women.

ABSTRACT:

Background

Cancer cachexia negatively impacts cancer-related treatment options, quality of life, morbidity, and mortality, yet no established therapies exist. We investigated the anabolic properties of testosterone to limit the loss of body mass in late stage cancer patients undergoing standard of care cancer treatment.

Methods

A randomized, double-blind, placebo-controlled phase II clinical trial was undertaken to assess the potential therapeutic role of adjunct testosterone to limit loss of body mass in patients with squamous cell carcinoma of the cervix or head and neck undergoing standard of care treatment including chemotherapy and chemoradiation. Patients were randomly assigned in blocks to receive weekly injections of either 100 mg testosterone enanthate or placebo fo

SUBMITTER: Wright TJ 

PROVIDER: S-EPMC5989774 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature